Photolabile carbonyl protecting group: A new tool for light-controlled release of anticancer agents

European Journal of Organic Chemistry

Volumn , Issue 13, 2009, Pages 2055-2058

  Wang, Pengfei ^a   Mondal, Mukulesh ^a   Wang, Yun ^a  

^a UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

Author keywords

Antitumor agents; Drug delivery; Phosphorus; Photolabile groups; Prodrugs; Protecting groups

Indexed keywords

EID: 66149115099     PISSN: 1434193X     EISSN: 10990690     Source Type: Journal    
DOI: 10.1002/ejoc.200900093     Document Type: Article

References (35)

1. a) B. A. Chabner, J. M. Collins (Eds.), Cancer Chemotherapy: Principles and Practice, J. L. Lippincott, Philadelphia, PA, 1991;
2. b) E. Watson, P. Dea, K. K. Chan, J. Pharm. Sci. 1985, 74, 1283-92;
3. c) V. L. Boyd, J. D. Robbins, W. Egan, S. M. Lude- man, J. Med. Chem. 1986, 29, 1206-1210.
4. For recent reviews of CP and related prodrugs, see: a) J. Zhang, Q. Tian, S.-F. Zhou, Curr. Drug Ther. 2006, 1,55-84;
5. b) M. E. Colvin, J. N. Quong, Advances in DNA Sequence-Specific Agents 2002, 4,29-46;
6. c) S. M. Ludeman, Biomed. Chem. 2000, 163-187;
7. d) S. M. Ludeman, Curr. Pharm. Des. 1999, 5, 627-643;
8. e) J. E. Wright, Cancer Ther. 1997,23-79;
9. f) J. Liang, M. Huang, W. Duan, X.-Q. Yu, S. Zhou, Curr. Pharm. Des. 2007, 13, 963-78;
10. g) C. T. Dang, Expert Rev. Anticancer Ther. 2006, 6, 427-436;
11. h) K. Misiura, Mini-Rev. Med. Chem. 2006, 6, 395-400;
12. i) J. Zhang, Q. Tian, S. Y. Chan, S. C. Li, S. Zhou, W. Duan, Y.-Z. Zhu, Drug Metabolism Rev. 2005, 37, 611-703;
13. j) P. H. Rooney, C. Telfer, M. C. E. McFadyen, M. T. Melvin, G. I. Murray, Curr. Cancer Drug Targets 2004, 4, 257-265;
14. k) E. A. Chiocca, D. J. Waxman, Methods Mol. Med. 2004, 90, 203-222.
15. a) V. T. Vu, C. C. Fenselau, M. Colvin, J. Am. Chem. Soc. 1981, 103, 7362-7364;
16. b) K. Hemminki, Cancer Res. 1985, 45, 4237-4243.
17. a) L. F. Tietze, T. Feuerstein, Curr. Pharm. Des. 2003, 9, 2155-2175 and references cited therein;
18. b) M. Jain, C.-H. Kwon, J. Med. Chem. 2003, 46, 5428-5436.
19. T. J. Dougherty, C. H. Gomer, B. W. Henderson, G. Jori, D. Kessel, M. Korbelik, J. Moan, Q. Peng, J. Natl. Cancer Inst. 1998, 90, 889-905.
20. a) P. Wang, H. Hu, Y. Wang, Org. Lett. 2007, 9, 1533-1535;
21. b) P. Wang, H. Hu, Y. Wang, Org. Lett. 2007, 9, 2831-2833;
22. c) P. Wang, Y. Wang, H. Hu, C. Spencer, X. Liang, L. Pan, J. Org. Chem. 2008, 73, 6152-6157.
23. P. Wang, Y. Wang, H. Hu, X. Liang, Eur. J. Org. Chem. 2009, 208-211.
24. a) It is well established that PEG improves the aqueous solubility, circulation half-life, and other pharmacokinetic properties of a drug. It is also known that PEG conjugates (MW > 10 K Dalton) have higher accumulation in tumors than in normal tissues as a result of the "enhanced permeation and retention effect" associated with macromolecules;
25. b) R. B. Greenwald, Y. H. Choe, J. McGuire, C. D. Conover, Adv. Drug Delivery Rev. 2003, 55, 217-250.
26. 31P NMR spectra were recorded at 161.97 MHz and chemical shifts were measured relative to external H3PO4 (85 %) in a coaxial capillary tube.
27. a) R. F. Borch, T. R. Hoye, T. A. Swanson, J. Med. Chem. 1984, 27, 490-494;
28. b) G. Zon, S. M. Ludeman, E. M. Sweet, W. Egan, L. R. Phillips, J. Pharm. Sci. 1982, 71, 443-446.
29. The chemical shifts of the intermediates are not identical to the values reported by others,[10,12] owing to the sensitivity of 31P NMR chemical shifts to the different experimental conditions. However, the growth of the signals and the disappearance pattern support the assignments.
30. a) T. W. Engle, G. Zon, W. Egan, J. Med. Chem. 1982, 25, 1347-1357;
31. b) T. W. Engle, G. Zon, W. Egan, J. Med. Chem. 1979, 22, 897-899;
32. c) E. M. Shulman-Roskes, D. A. Noe, M. P. Gamcsik, A. L. Marlow, J. Hilton, F. H. Hausheer, M. Colvin, S. M. Ludeman, J. Med. Chem. 1998, 41, 515-529.
33. P. Wang, Y. Song, L. Zhang, H. He, X. Zhou, Curr. Med. Chem. 2005, 12, 2893-913.
34. a) E. Wrabetz, G. Peter, H.J. Hohorst, J. Cancer Res. Clin. Oncol. 1980, 98, 119-126;
35. b) P.J. Cox, Biochem. Pharmacol. 1979, 28, 2045-2049.